Download het volledig rapport (302 p.) - KCE

KCE reports vol. 6A Prenatale zorg 138
Study Ref Population Intervention Outcomes Results Comments Study
type
EL
al., 2002
pregnancy vs. placebo Very preterm births (n OR 0.86 (95% CI 0.57 to the trials (p = 0.37)
Cochrane review
or micronutrient = 1578, 2 RCTs) 1.31)
supplementation All preterm births (n = OR 0.88 (95% CI 0.68 to ** There were only 3
Most recent update 2002
1577, 2 RCTs) 1.13)
maternal deaths
Low birth weight (n = OR 0.71 (95% CI 0.40 to
1486, 2 RCTs) 1.28)
Very low birth weight OR 0.71 (95% CI 0.40 to
(n = 1483, 2 RCTs) 1.28)
Postpartum CD4 levels
(n = 727, 1 RCT)
Weighted mean
difference 4.0, 95% CI
51.06 to 43.06
Maternal death (n = OR 0.49 (95% CI 0.04 to
728, 1 RCT)** 5.40)
Ricci and 4 436 women between 34 to 38 Caesarean section Adverse effects of Higher rates of fever in Analysis by actual mode RCT 1b
Parazzini, [418] weeks pregnancy with delivery vs. vaginal delivery in HIV1 women who gave births of delivery
2000
confirmed HIV-1 diagnosis delivery
infected women (i.e., by Caesarean section, but
without indication (or
fever, wound infection, no significant differences
contraindication) for
anaesthetic, anaemia, in complication rates
caesarean section delivery in
other)
between women treated
various European countries,
with zidovudine in
including the UK
pregnancy and those not
treated
Cunningham 4 242 from original PACTG Emergence of Detection of resistance Detection of resistance International,
OB 3
et al., 2002 [419] (only US and French sites nevirapine resistance mutations prior to mutations prior to multicentre substudy of
included) study with 25 mutations at 6 weeks receipt of study drug receipt of study drug: PACTG 316
excluded from final analysis postpartum in women
5/217 women (2.3%)
receiving standard Detection of resistance
Risk for development of
(RCT substudy)
antiretroviral treatment mutations at 6 weeks Detection of resistance resistant mutations not
postpartum among mutations at 6 weeks correlated with CD4
women who received postpartum among cell counts or HIV-1
the study drug (single women who received the RNA viral load at
dose oral 200 mg to study drug: 14/95 (15%, delivery or with type of
mother and 2 mg/kg to 95% CI 8 to 23%) antiretroviral therapy